According to the World Health Organization (WHO),
around 570,000 women died due to breast cancer in 2015. Moreover,
according to the Centers for Disease Control and Prevention (CDC),
around 236,968 women diagnosed with breast cancer among which around
41,211 women died in 2014. The data indicating a high prevalence of
chronic diseases affects lifestyle of women day-by-day. Growing
demand for early stage diagnosis of infection/diseases needs new
rapid diagnostic tests and imaging system which is expected to fuel
the growth of women’s health diagnostic test market in the near
future.
Download PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/971
In 2017, Naugatuck Valley Women’s Health
Specialists (NVWHS) decided to provide a free informational program
for heart health with Boston Heart Diagnostics. Boston Heart
diagnostics has anticipating treatment and diagnosis of
cardiovascular diseases (CVD), which improves women’s heart health,
as CVD is a leading disease in the U.S. This program is expected to
create awareness of CVD related diseases among women and also help to
improve lifestyle.
In 2017, Mission Hope Cancer Center accredited by
the National Accreditation Program for Breast Cancer Centers (NAPBC)
joined Dignity Health Central Coast hospitals. In Mission Hope’s
cancer care program, breast cancer examination services and facility
is expected to be provided to women. Moreover, in 2017, Dignity
Health installed 3D imaging technology - Mammography in the central
coast. This technology helps in detection of breast cancer before
symptomatic stage, which increases 98% survival rate. Thus, this
program is expected to create more awareness and early detection of
cancer, which in turn is expected to augment the growth of women’s
health diagnostic test market.
In 2016, Aeon Clinical Labs launched a RUO women’s
health panel test, which is developed by Thermo Fischer Scientific.
This test is based on PCR that detects 34 different target include
candidiasis, bacterial vaginosis, and sexual transmitted diseases
such as gonorrhea, chlamydia, and some others. Aeon is further aiming
to expand genetic assays for pharmacogenomics and hereditary cancer
in the near future.
Get Exclusive Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/971
According to National Cancer Institute (NCI), in
2016, around 22,280 women diagnosed with ovary cancer and around
14,240 women died due to ovary cancer in U.S. Furthermore, according
to Cancer Research UK, in 2014, around 7,378 new cases of ovary
cancer and around 55,222 cases of breast cancer were diagnosed in
U.K. Moreover, around 20 cases of ovarian cancers are diagnosed every
day and is projected to increase by 15% by 2035.
Some of the key players operating in the global
women’s health diagnostic test market include Biomerieux SA, F.
Hoffmann-LA Roche AG, Becton, Dickinson and Company, Siemens AG,
Abbott Laboratories, Hologic, Inc., Koninklijke Philips N.V., Quest
Diagnostics Inc., GE Healthcare, and Alere Inc.
Click To Continue Reading On Women’s
Health Diagnostic Test Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market
research and consulting firm offering action-ready syndicated
research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
Mr.
Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
No comments:
Post a Comment